Pfizer’s combo pill could reinvigorate troubled HRT market
This article was originally published in Scrip
Executive Summary
New positive Phase III data suggests Pfizer’s new combination pill BZA/CE is safe and effective in treating menopausal symptoms and preventing osteoporosis. While this is promising, approval is not guaranteed as the FDA has had a tough stance on such therapies. Assuming it reaches the US market in 2013, the challenge for Pfizer will be to dispel safety concerns associated with women taking HRT.